UK NHS review finds benefit in combining PET/CT to assess breast cancer recurrence
This article was originally published in Clinica
Executive Summary
A review for the UK’s National Health Service of the use of positron emission tomography (PET) and computed tomography (CT) in prognosing breast cancer recurrence has found that the combination of the two technologies “offers improved diagnostic accuracy compared to conventional imaging tests”. However, “uncertainty remains around its use as a replacement for, rather than as an add-on to, existing technologies”, concluded a team of researchers from the West Midlands Health Technology Assessment Collaboration (WMHTAC) at the University of Birmingham. The systematic review, which appears in the current issue of the journal Health Technology Assessment, was conducted on behalf of the Evaluation, Trials and Studies Coordinating Centre (NETSCC) of the National Institute for Health Research (NIHR).
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.